Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 291.1 USD | -1.27% |
|
-9.92% | +1.08% |
| Feb. 07 | Global markets live: Amgen, Chipotle, Ford, Gilead, VF Corp... |  |
| Feb. 07 | Abivax appoints new head of quality | CF |
Financials (USD)
| Sales 2023 | 28.19B | Sales 2024 * | 32.83B | Capitalization | 156B |
|---|---|---|---|---|---|
| Net income 2023 | 6.72B | Net income 2024 * | 6.02B | EV / Sales 2023 | 7.37 x |
| Net Debt 2023 | 53.67B | Net Debt 2024 * | 47.43B | EV / Sales 2024 * | 6.19 x |
| P/E ratio 2023 |
23.1
x | P/E ratio 2024 * |
25.1
x | Employees | 25,200 |
| Yield 2023 |
2.96% | Yield 2024 * |
3.18% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -1.27% | ||
| 1 week | -9.92% | ||
| Current month | -7.36% | ||
| 1 month | -5.25% | ||
| 3 months | +10.25% | ||
| 6 months | +12.26% | ||
| Current year | +1.08% |
1 week
288.78
329.72
1 month
288.78329.72
Current year
287.28329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
108.20329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 115 M€ | +8.40% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 291.1 | -1.27% | 3,341,055 |
| 24-02-08 | 294.8 | -0.34% | 5,946,119 |
| 24-02-07 | 295.9 | -6.39% | 8,411,337 |
| 24-02-06 | 316.1 | -1.83% | 5,767,390 |
| 24-02-05 | 322 | -0.38% | 3,563,345 |
Delayed Quote Nasdaq, February 09, 2024 at 04:00 pm EST
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-02-14
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
291.1
USD
Average target price
300.8
USD
Spread / Average Target
+3.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.08% | 156 B $ | |
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| -8.02% | 207 B $ | |
| +4.05% | 206 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ |
